long intergenic non-protein coding RNA 1713Genealiases: []
Q-omics provides the consensus-scored LINC01713 profile across patient tissues and cancer cell-line models. LINC01713 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01713 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC01713 RNA expression shows 6,947 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where LINC01713 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01713 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01713 survival associations across molecular data types. LINC01713 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01713 RNA expression–survival associations across cancer types. High LINC01713 expression shows unfavorable associations in LIHC and BLCA, but favorable associations in ESCA, LGG, MESO and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01713 RNA expression.
This table summarizes LINC01713 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01713. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01713 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, PAAD and ESCA. The KIRC box plot shows higher LINC01713 RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p < 0.001).
This table shows molecular features associated with LINC01713 in patient tissues and cancer cell lines. In patient samples, LINC01713 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
